Barrett & Company’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$998K Sell
862
-122
-12% -$144K 0.27% 53
2026
Q2
$1.18M Buy
984
+464
+89% +$474K 0.33% 45
2026
Q1
$478K Buy
520
+4
+0.8% +$4.06K 0.16% 85
2025
Q4
$555K Sell
516
-6
-1% -$5.74K 0.19% 81
2025
Q3
$398K Sell
522
-221
-30% -$164K 0.14% 93
2025
Q2
$579K Buy
743
+3
+0.4% +$2.33K 0.22% 74
2025
Q1
$611K Buy
740
+1
+0.1% +$832 0.26% 68
2024
Q4
$571K Buy
739
+3
+0.4% +$2.48K 0.24% 71
2024
Q3
$652K Sell
736
-316
-30% -$284K 0.28% 64
2024
Q2
$953K Buy
1,052
+1
+0.1% +$800 0.43% 43
2024
Q1
$818K Buy
1,051
+267
+34% +$190K 0.39% 49
2023
Q4
$457K Sell
784
-338
-30% -$197K 0.25% 79
2023
Q3
$602K Buy
1,122
+9
+0.8% +$4.64K 0.35% 58
2023
Q2
$522K Buy
1,113
+2
+0.2% +$839 0.3% 66
2023
Q1
$381K Buy
1,111
+4
+0.4% +$1.35K 0.24% 82
2022
Q4
$405K Hold
1,107
– – 0.27% 76
2022
Q3
$405K Buy
+1,107
New +$351K 0.27% 76

Other funds holding LLY

Barrett & Company's LLY Position: Q3 2026 in Review

Barrett & Company reduced its Eli Lilly (LLY) stake by 12% in Q3 2026, selling an estimated $144K and leaving 862 shares worth $998K. The position accounts for 0.27% of the portfolio, ranked #53.

Barrett & Company first reported a position in LLY in Q3 2022 and has held it in 17 quarters since. The position peaked at $1.18M in Q2 2026. 1,679 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Barrett & Company held 862 shares of Eli Lilly worth $998K as of Q3 2026.
  • Barrett & Company sold 122 Eli Lilly shares in Q3 2026, an estimated $144K.
  • Eli Lilly made up 0.27% of Barrett & Company's portfolio in Q3 2026, its #53 holding.
  • Barrett & Company first reported a position in Eli Lilly in Q3 2022 and has held it in 17 quarters since.
  • Barrett & Company's Eli Lilly position peaked at $1.18M in Q2 2026.
  • 1,679 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Barrett & Company's 13F filing for Q3 2026, filed 22 Oct 2026.